Frankincense myrrh attenuates hepatocellular carcinoma by regulating tumor blood vessel development through multiple epidermal growth factor receptor-mediated signaling pathways

Figure 10 The effect of frankincense and/or myrrh on EGFR, PI3K/Akt and MAPK (ERK, p38, JNK) pathway components. A and B: The protein levels of EGFR, p-EGFR in tumor body; C-E: The protein levels of PI3K, p-PI3K, Akt, p-Akt in tumor body; F-I: The protein levels of EKR, p-ERK, p38, p-p38, JNK, p-JNK. The protein expression indicated with Western blot, and GAPDH was used as internal control. Data represents the mean ± SE. LF: Low dose of frankincense extract; HF: High dose of frankincense extract; LM: Low dose of myrrh extract; HM: High dose of myrrh extract; LFM: Low dose of frankincense + myrrh extracts; HFM: High dose of frankincense + myrrh extracts. Data represents the mean ± SE. ^aP < 0.05 vs the model control; ^bP < 0.05 vs ZD1839; ^cP < 0.05 vs low dose of frankincense + myrrh extracts; ^dP < 0.05 vs high dose of frankincense + myrrh extracts.